Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8316758 | Clinica Chimica Acta | 2011 | 5 Pages |
Abstract
The eSensor CYP2C19 genotyping assay is accurate and compares well with 2 current commercial platforms. With a relatively rapid turn-around time of ~Â 4Â h and a high rate (97.5%) of valid tests, the eSensor can be translated into clinical use to identify slow and rapid metabolizers of clopidogrel who may benefit from alternate therapy or unconventional dosing of clopidogrel. An observed limitation of the eSensor is a maximum capacity of 24 tests/run.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Biochemistry
Authors
Christine C. Lee, Gwendolyn A. McMillin, Nikolina Babic, Roberta Melis, Kiang-Teck J. Yeo,